caption
stringlengths 0
3.92k
| molecule
stringlengths 1
914
| properties
sequencelengths 1
113
| additional_data
dict |
|---|---|---|---|
The molecule is a hpk1 antagonist. | CC(C)N(C)Cc1nc(NC(=O)OC(C)(C)C)ccc1C1CCOC1 | [
"hpk1 antagonist"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, fat storage, energy storage, membrane stabilizer that impacts metabolic syndrome and cancer. The molecule is a inflammatory and belongs to the thyroxine treatment class of molecules, impacting atherosclerosis. The molecule is a energy source that impacts obesity, pancreatitis, and cardiovascular disease. | CCC(C)CCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCC(C)C | [
"nutrient",
"Fat storage",
"Metabolic syndrome",
"Cancer",
"Energy storage",
"Membrane stabilizer",
"inflammatory",
"Thyroxine treatment",
"Atherosclerosis",
"Obesity",
"Pancreatitis",
"Cardiovascular disease",
"Energy source"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient and thyroxine treatment, and it impacts cardiovascular disease. The molecule is a fat storage that impacts atherosclerosis, pancreatitis, and metabolic syndrome. | CCCC/C=C\CCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCC/C=C\CCCCCCCC)OCCCCCCCCCCCCCCCCCC | [
"nutrient",
"Cardiovascular disease",
"Thyroxine treatment",
"Atherosclerosis",
"Fat storage",
"Pancreatitis",
"Metabolic syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that is sweet and cotton. The molecule is candy, powdery, heliotrope, and raspberry. | CC(C)C1C=CC(=O)O1 | [
"sweet",
"cotton",
"nutrient",
"candy",
"powdery",
"heliotrope",
"raspberry"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation that impacts diabetic heart disease, non-alcoholic fatty liver disease, aging, and barth syndrome. The molecule is a stabilizing mitochondrial structure, cholesterol translocation, apoptosis, stabilizing cytochrome oxidase that impacts tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Aging",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
CC(=C)C1CCC2(C1C3CCC4C5(CCC(C(C5CCC4(C3(CC2)C)C)(C)C)O)C)CO.CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)O)C)C)C2C1)C)CO)C.CC(=C)C1CCC2(C1C3CCC4C5(CCC(C(C5CCC4(C3(CC2)C)C)(C)C)O)C)C(=O)O.CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)O)C)C)C2C1)C)C(=O)O)C.CC(=C)C1CCC2(C1C3CCC4C5(CCC(C(C5CCC4(C3(CC2)C)C)(C)C)O)C)C | [
"Mystery Molecule"
] | {
"Actives": "birch triterpenes",
"Approval Date": "12/18/2023",
"Brand Name": "Filsuvez",
"Indication": "To treat wounds associated with dystrophic and junctional epidermolysis bullosa",
"PubChem CIDs": [
"72326",
"101761",
"64971",
"10494",
"259846"
]
} |
|
CCOC1CCN(C(C1)C2=CC=C(C=C2)C(=O)O)CC3=C(C=C(C4=C3C=CN4)C)OC | [
"Mystery Molecule"
] | {
"Actives": "iptacopan",
"Approval Date": "12/5/2023",
"Brand Name": "Fabhalta",
"Indication": "To treat paroxysmal nocturnal hemoglobinuria",
"PubChem CIDs": [
"90467622"
]
} |
|
CCCC(C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C)NC2CCC3=C(C2)C(=CC(=C3)F)F | [
"Mystery Molecule"
] | {
"Actives": "nirogacestat",
"Approval Date": "11/27/2023",
"Brand Name": "Ogsiveo",
"Indication": "To treat adults with progressing desmoid tumors who require systemic treatment",
"PubChem CIDs": [
"46224413"
]
} |
|
C1CN(CCC1(C(=O)NC(CCO)C2=CC=C(C=C2)Cl)N)C3=NC=NC4=C3C=CN4 | [
"Mystery Molecule"
] | {
"Actives": "capivasertib",
"Approval Date": "11/16/2023",
"Brand Name": "Truqap",
"Indication": "To treat breast cancer that meets certain disease criteria",
"PubChem CIDs": [
"25227436"
]
} |
|
CC1CNC(=O)C2=C3N=C(C=CN3N=C2)NC(C4=C(O1)C=CC(=C4)F)C | [
"Mystery Molecule"
] | {
"Actives": "repotrectinib",
"Approval Date": "11/15/2023",
"Brand Name": "Augtyro",
"Indication": "To treat ROS1-positive non-small cell lung cancer",
"PubChem CIDs": [
"135565923"
]
} |
|
O=S1(=O)CCN(CN2CCS(=O)(=O)NC2)CN1.CC(=O)NC(C=O)C(O)C(OC1OC(=CC(O)C1O)C(O)=O)C(O)CO | [
"Mystery Molecule"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
|
CC1=C(C2=C(O1)C=C(C=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(=O)NC | [
"Mystery Molecule"
] | {
"Actives": "fruquintinib",
"Approval Date": "11/8/2023",
"Brand Name": "Fruzaqla",
"Indication": "To treat refractory, metastatic colorectal cancer",
"PubChem CIDs": [
"44480399"
]
} |
|
CC1CC2C3CCC4=CC(=O)C=CC4(C3=CCC2(C1(C(=O)CO)O)C)C | [
"Mystery Molecule"
] | {
"Actives": "vamorolone",
"Approval Date": "10/26/2023",
"Brand Name": "Agamree",
"Indication": "To treat Duchenne muscular dystrophy",
"PubChem CIDs": [
"3035000"
]
} |
|
CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCC(=O)NCCCCC(C(=O)O)NC(=O)C(C1CCCCC1)NC(=O)C2CCCN2C(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(CCC(=O)O)NC(=O)C(CC4=CNC5=C4C=CC=N5)NC(=O)C(CC6=CC=C(C=C6)O)NC(=O)C(C(C)(C)C)NC(=O)C(CC(=O)O)N(C)C(=O)C7CC(=O)NCCCCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N7)CC8=CC=CC=C8)CCCNC(=N)N)CCC(=O)O)C(C)C)NC(=O)C)C(=O)O | [
"Mystery Molecule"
] | {
"Actives": "zilucoplan",
"Approval Date": "10/17/2023",
"Brand Name": "Zilbrysq",
"Indication": "To treat generalized myasthenia gravis in adults who are anti-acetylcholine receptor (AChR) antibody positive",
"PubChem CIDs": [
"133083018"
]
} |
|
C1CCC(C1)C2=C(C=C(C=C2)COC3=CC4=C(C=C3)NC5=C4CCC5CC(=O)O)C(F)(F)F | [
"Mystery Molecule"
] | {
"Actives": "etrasimod",
"Approval Date": "10/12/2023",
"Brand Name": "Velsipity",
"Indication": "To treat moderately to severely active ulcerative colitis in adults",
"PubChem CIDs": [
"44623998"
]
} |
|
CC1(CC(=O)N(C(=O)C1)CCCCN2CCN(CC2)C3=NC=CC=N3)C | [
"Mystery Molecule"
] | {
"Actives": "gepirone",
"Approval Date": "9/22/2023",
"Brand Name": "Exxua",
"Indication": "To treat major depressive disorder",
"PubChem CIDs": [
"55191"
]
} |
|
C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N | [
"Mystery Molecule"
] | {
"Actives": "momelotinib",
"Approval Date": "9/15/2023",
"Brand Name": "Ojjaara",
"Indication": "To treat intermediate or high-risk myelofibrosis in adults with anemia",
"PubChem CIDs": [
"25062766"
]
} |
|
C1CC2C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2C1)CCCCN)CCCCN)CCCNC(=O)N)CC3=CC=C(C=C3)O)NC(=O)C(CC4=CC5=CC=CC=C5C=C4)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCCNC(=N)N)NC(=O)C6=CC=C(C=C6)F)C(=O)NC(CCCNC(=N)N)C(=O)N)CCCNC(=O)N)CCCNC(=N)N)CC7=CC=C(C=C7)O | [
"Mystery Molecule"
] | {
"Actives": "motixafortide",
"Approval Date": "9/8/2023",
"Brand Name": "Aphexda",
"Indication": "To use with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma",
"PubChem CIDs": [
"91865076"
]
} |
|
CC1(CCC(C2=C1C=C(C(=C2)C=CC3=CC=C(C=C3)C(=O)O)CN4C=CC=N4)(C)C)C | [
"Mystery Molecule"
] | {
"Actives": "palovarotene",
"Approval Date": "8/16/2023",
"Brand Name": "Sohonos",
"Indication": "To reduce the volume of new heterotopic ossification in adults and pediatric patients (aged 8 years and older for females and 10 years and older for males) with fibrodysplasia ossificans progressiva",
"PubChem CIDs": [
"10295295"
]
} |
|
CC1(CCC2C(C1)CCC3C2CCC4(C3CCC4C(=O)CN5C=C(C=N5)C#N)C)O | [
"Mystery Molecule"
] | {
"Actives": "zuranolone",
"Approval Date": "8/4/2023",
"Brand Name": "Zurzuvae",
"Indication": "To treat postpartum depression ",
"PubChem CIDs": [
"86294073"
]
} |
|
CC1=C(SC(=C1)C2=NOC(C2)(C3=CC(=C(C(=C3)Cl)Cl)Cl)C(F)(F)F)C(=O)NCC(=O)NCC(F)(F)F | [
"Mystery Molecule"
] | {
"Actives": "lotilaner",
"Approval Date": "7/25/2023",
"Brand Name": "Xdemvy",
"Indication": "To treat Demodex blepharitis",
"PubChem CIDs": [
"76959255"
]
} |
|
CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C=C2)C3=CN4C5=C(C=C(C=C5)OCCN6CCOCC6)SC4=N3 | [
"Mystery Molecule"
] | {
"Actives": "quizartinib",
"Approval Date": "7/20/2023",
"Brand Name": "Vanflyta",
"Indication": "To use as part of a treatment regimen for newly diagnosed acute myeloid leukemia that meets certain criteria",
"PubChem CIDs": [
"24889392"
]
} |
|
CC1CCC(CN1C(=O)C=C)NC2=NC=NC3=C2C=CN3 | [
"Mystery Molecule"
] | {
"Actives": "ritlecitinib",
"Approval Date": "6/23/2023",
"Brand Name": "Litfulo",
"Indication": "To treat severely patchy hair loss",
"PubChem CIDs": [
"118115473"
]
} |
|
CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)SC)O)O)O)Cl | [
"Mystery Molecule"
] | {
"Actives": "sotagliflozin",
"Approval Date": "5/26/2023",
"Brand Name": "Inpefa",
"Indication": "To treat heart failure ",
"PubChem CIDs": [
"24831714"
]
} |
|
CC(C)(C)[Si](C1=CC=C(C=C1)C(=O)NCC(C(=O)NC(CCCCNC(=O)CCC(=O)NCCCC(C(=O)O)NC(=O)CCC(C(=O)O)NC(=O)NC(CCC(=O)O)C(=O)O)C(=O)O)NC(=O)CCC(C(=O)O)N2CCN(CCN(CCN(CC2)CC(=O)O)CC(=O)O)CC(=O)O)(C(C)(C)C)F | [
"Mystery Molecule"
] | {
"Actives": "flotufolastat F 18",
"Approval Date": "5/25/2023",
"Brand Name": "Posluma",
"Indication": "To use with positron emission tomography imaging in certain patients with prostate cancer",
"PubChem CIDs": [
"154572844"
]
} |
|
CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)C(F)(F)F)C(=O)NC(CC3CCNC3=O)C#N)C.CC(C)C1=NC(=CS1)CN(C)C(=O)NC(C(C)C)C(=O)NC(CC2=CC=CC=C2)CC(C(CC3=CC=CC=C3)NC(=O)OCC4=CN=CS4)O | [
"Mystery Molecule"
] | {
"Actives": "nirmatrelvir, ritonavir",
"Approval Date": "5/25/2023",
"Brand Name": "Paxlovid",
"Indication": "To treat mild-to-moderate COVID-19 in adults at high risk for progression to severe COVID-19",
"PubChem CIDs": [
"155903259",
"392622"
]
} |
|
CC1(C(N2C(S1(=O)=O)CC2=O)C(=O)O)C.CC1=CC2CN(C1C(=O)N)C(=O)N2OS(=O)(=O)O | [
"Mystery Molecule"
] | {
"Actives": "sulbactam, durlobactam",
"Approval Date": "5/23/2023",
"Brand Name": "Xacduro",
"Indication": "To treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex",
"PubChem CIDs": [
"130313",
"89851852"
]
} |
|
CCCCCCCCC(C(C(C(C(C(F)(F)F)(F)F)(F)F)(F)F)(F)F)(F)F | [
"Mystery Molecule"
] | {
"Actives": "perfluorhexyloctane",
"Approval Date": "5/18/2023",
"Brand Name": "Miebo",
"Indication": "To treat signs and symptoms of dry eye disease",
"PubChem CIDs": [
"10477896"
]
} |
|
CC1C2=NN=C(N2CCN1C(=O)C3=CC=C(C=C3)F)C4=NC(=NS4)C | [
"Mystery Molecule"
] | {
"Actives": "fezolinetant",
"Approval Date": "5/12/2023",
"Brand Name": "Veozah",
"Indication": "To treat moderate to severe hot flashes caused by menopause",
"PubChem CIDs": [
"117604931"
]
} |
|
CCC(=O)N1CCC(C1)NC2=NC=NC3=C2CN(CC3)C4=CC(=C(N=C4)OC)C(F)(F)F | [
"Mystery Molecule"
] | {
"Actives": "leniolisib",
"Approval Date": "3/24/2023",
"Brand Name": "Joenja",
"Indication": "To treat activated phosphoinositide 3-kinase delta syndrome",
"PubChem CIDs": [
"57495353"
]
} |
|
CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC=C(C=C7)O)O)O)C(C)O)C)O)OCC[N+](C)(C)C)O | [
"Mystery Molecule"
] | {
"Actives": "rezafungin",
"Approval Date": "3/22/2023",
"Brand Name": "Rezzayo",
"Indication": "To treat candidemia and invasive candidiasis",
"PubChem CIDs": [
"78318119"
]
} |
|
CC1(CCCN1C(=O)CN)C(=O)NC(CCC(=O)O)C(=O)O | [
"Mystery Molecule"
] | {
"Actives": "trofinetide",
"Approval Date": "3/10/2023",
"Brand Name": "Daybue",
"Indication": "To treat Rett syndrome",
"PubChem CIDs": [
"11318905"
]
} |
|
CC1=CC(=CC2=C1NN=C2)CC(C(=O)N3CCN(CC3)C4CCN(CC4)C)NC(=O)N5CCC(CC5)C6=CC7=CC=CC=C7NC6=O | [
"Mystery Molecule"
] | {
"Actives": "zavegepant",
"Approval Date": "3/9/2023",
"Brand Name": "Zavzpret",
"Indication": "To treat migraine",
"PubChem CIDs": [
"53472683"
]
} |
|
CC1(CCC2(CCC3(C(C2C1)C(=O)C=C4C3(CCC5C4(C=C(C(=O)C5(C)C)C#N)C)C)C)NC(=O)C(C)(F)F)C | [
"Mystery Molecule"
] | {
"Actives": "omaveloxolone",
"Approval Date": "2/28/2023",
"Brand Name": "Skyclarys",
"Indication": "To treat Friedrich’s ataxia",
"PubChem CIDs": [
"71811910"
]
} |
|
CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC | [
"Mystery Molecule"
] | {
"Actives": "sparsentan",
"Approval Date": "2/17/2023",
"Brand Name": "Filspari",
"Indication": "To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression",
"PubChem CIDs": [
"10257882"
]
} |
|
C1CCC(CC1)N2C(=O)C(C(=O)N(C2=O)C3CCCCC3)C(=O)NCC(=O)O | [
"Mystery Molecule"
] | {
"Actives": "daprodustat",
"Approval Date": "2/1/2023",
"Brand Name": "Jesduvroq",
"Indication": "To treat anemia caused by chronic kidney disease for adults on dialysis for at least four months",
"PubChem CIDs": [
"91617630"
]
} |
|
CCNCCC1=CC=C(C=C1)CN(CC)C2=C(C=CC(=C2)OC)C3CCC4=C(C3)C=CC(=C4)O | [
"Mystery Molecule"
] | {
"Actives": "elacestrant ",
"Approval Date": "1/27/2023",
"Brand Name": "Orserdu",
"Indication": "To treat estrogen receptor-positive, human epidermal growth factor receptor 2-negative, ESR1-mutated, advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy",
"PubChem CIDs": [
"23642301"
]
} |
|
CC(C(F)(F)F)N1C(=C(C(=N1)C2=CC=C(C=C2)CNC(=O)C3=C(C=CC(=C3)F)OC)C(=O)N)N | [
"Mystery Molecule"
] | {
"Actives": "pirtobrutinib",
"Approval Date": "1/27/2023",
"Brand Name": "Jaypirca",
"Indication": "To treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitor",
"PubChem CIDs": [
"129269915"
]
} |
|
C1CC1OCCOC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl | [
"Mystery Molecule"
] | {
"Actives": "bexagliflozin",
"Approval Date": "1/20/2023",
"Brand Name": "Brenzavvy",
"Indication": "To improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise",
"PubChem CIDs": [
"25195624"
]
} |
|
CCN(CC)CC1=CC2=C(C=C1)C=C(C=C2)COC(=O)NC3=CC=C(C=C3)C(=O)NO | [
"Mystery Molecule"
] | {
"Actives": "givinostat",
"Approval Date": "3/21/2024",
"Brand Name": "Duvyzat",
"Indication": "To treat Duchenne muscular dystrophy in individuals aged 6 years and older",
"PubChem CIDs": [
"9804992"
]
} |
|
C1=CC(=CC=C1C2=C(N=CN=C2OCCOC3=NC=C(C=N3)Br)NS(=O)(=O)N)Br | [
"Mystery Molecule"
] | {
"Actives": "aprocitentan",
"Approval Date": "3/19/2024",
"Brand Name": "Tryvio",
"Indication": "To treat hypertension",
"PubChem CIDs": [
"25099191"
]
} |
|
CC(C)C1=CC(=NNC1=O)OC2=C(C=C(C=C2Cl)N3C(=O)NC(=O)C(=N3)C#N)Cl | [
"Mystery Molecule"
] | {
"Actives": "resmetirom",
"Approval Date": "3/14/2024",
"Brand Name": "Rezdiffra",
"Indication": "To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring",
"PubChem CIDs": [
"15981237"
]
} |
|
C[N+]1(CCCC1)CC2=C(N3C(C(C3=O)NC(=O)C(=NOC)C4=CSC(=N4)N)SC2)C(=O)[O-] | [
"Mystery Molecule"
] | {
"Actives": "cefepime",
"Approval Date": "enmetazobactam",
"Brand Name": "Exblifep",
"Indication": "2/22/2024",
"PubChem CIDs": [
"5479537"
]
} |
|
[129Xe] | [
"Mystery Molecule"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
|
CC(C)(C#CC1=NC(=C(C=C1)C2=C3C(=C(C=C2)Cl)C(=NN3CC(F)(F)F)NS(=O)(=O)C)C(CC4=CC(=CC(=C4)F)F)NC(=O)CN5C6=C(C7CC7C6(F)F)C(=N5)C(F)(F)F)S(=O)(=O)C | [
"Mystery Molecule"
] | {
"Actives": "lenacapavir",
"Approval Date": "12/22/2022",
"Brand Name": "Sunlenca",
"Indication": "To treat adults with HIV whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance, or safety considerations",
"PubChem CIDs": [
"133082658"
]
} |
|
CN1CCCC1COC2=NC3=C(CCN(C3)C4=CC=CC5=C4C(=CC=C5)Cl)C(=N2)N6CCN(C(C6)CC#N)C(=O)C(=C)F | [
"Mystery Molecule"
] | {
"Actives": "adagrasib",
"Approval Date": "12/12/2022",
"Brand Name": "Krazati",
"Indication": "To treat KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer in adults who have received at least one prior systemic therapy",
"PubChem CIDs": [
"138611145"
]
} |
|
CC(C1=CC2=C(C=CC(=C2)Cl)NC1=O)NC3=CC=C(N(C3=O)C)C#N | [
"Mystery Molecule"
] | {
"Actives": "olutasidenib",
"Approval Date": "12/1/2022",
"Brand Name": "Rezlidhia",
"Indication": "To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation",
"PubChem CIDs": [
"118955396"
]
} |
|
COC1=CC(=CC(=C1)C#CC2=NN(C3=NC=NC(=C23)N)C4CCN(C4)C(=O)C=C)OC | [
"Mystery Molecule"
] | {
"Actives": "futibatinib",
"Approval Date": "9/30/2022",
"Brand Name": "Lytgobi",
"Indication": "To treat intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements",
"PubChem CIDs": [
"71621331"
]
} |
|
C1=CC=C(C=C1)CCCC(=O)[O-].[Na+].CC(CCC(=O)NCCS(=O)(=O)O)C1CCC2C1(CCC3C2C(CC4C3(CCC(C4)O)C)O)C | [
"Mystery Molecule"
] | {
"Actives": "sodium phenylbutyrate/taurursodiol",
"Approval Date": "9/29/2022",
"Brand Name": "Relyvrio",
"Indication": "To treat amyotrophic lateral sclerosis (ALS)",
"PubChem CIDs": [
"5258",
"9848818"
]
} |
|
CC(C)OC(=O)CNC1=CC=CC(=N1)CN(CC2=CC=C(C=C2)N3C=CC=N3)S(=O)(=O)C4=CN=CC=C4 | [
"Mystery Molecule"
] | {
"Actives": "oomidenepag isopropyl ophthalmic solution",
"Approval Date": "9/22/2022",
"Brand Name": "Omlonti",
"Indication": "To reduce elevated intraocular pressure in patients with open‑angle glaucoma or ocular hypertension",
"PubChem CIDs": [
"44230999"
]
} |
|
C1CN(CC2=NC(=CC=C2)CN(CCN1C(CCC(=O)NCC(CO)O)C(=O)[O-])C(CCC(=O)NCC(CO)O)C(=O)[O-])C(CCC(=O)NCC(CO)O)C(=O)[O-].[Gd+3] | [
"Mystery Molecule"
] | {
"Actives": "gadopiclenol",
"Approval Date": "9/21/2022",
"Brand Name": "Elucirem",
"Indication": "To detect and visualize lesions, together with MRI, with abnormal vascularity in the central nervous system and the body",
"PubChem CIDs": [
"16223405"
]
} |
|
C1CC(N(C1)C(=O)C2CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)NC(=O)CNC(=O)CNC(=O)CN)C(=O)NC(CCCCN)C(=O)NCC(=O)N | [
"Mystery Molecule"
] | {
"Actives": "terlipressin",
"Approval Date": "9/14/2022",
"Brand Name": "Terlivaz",
"Indication": "To improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function",
"PubChem CIDs": [
"72081"
]
} |
|
CNC(=O)C1=NN=C(C=C1NC2=CC=CC(=C2OC)C3=NN(C=N3)C)NC(=O)C4CC4 | [
"Mystery Molecule"
] | {
"Actives": "deucravacitinib",
"Approval Date": "9/9/2022",
"Brand Name": "Sotyktu",
"Indication": "To treat moderate-to-severe plaque psoriasis",
"PubChem CIDs": [
"134821691"
]
} |
|
CC(C)C1=C(C=C(C=C1O)C=CC2=CC=CC=C2)O | [
"Mystery Molecule"
] | {
"Actives": "tapinarof",
"Approval Date": "5/23/2022",
"Brand Name": "Vtama",
"Indication": "To treat plaque psoriasis",
"PubChem CIDs": [
"6439522"
]
} |
|
CCC(C)C(C(=O)NC(C)C(=O)NC(CCC(=O)N)C(=O)NC(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCCCC(=O)O)C(=O)NC(C)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)N)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NCC(=O)NCC(=O)N4CCCC4C(=O)NC(CO)C(=O)NC(CO)C(=O)NCC(=O)NC(C)C(=O)N5CCCC5C(=O)N6CCCC6C(=O)N7CCCC7C(=O)NC(CO)C(=O)N)NC(=O)C(CCCCN)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(C)(C)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(CC8=CC=C(C=C8)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC9=CC=CC=C9)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)(C)NC(=O)C(CC1=CC=C(C=C1)O)N | [
"Mystery Molecule"
] | {
"Actives": "tirzepatide",
"Approval Date": "5/13/2022",
"Brand Name": "Mounjaro",
"Indication": "To improve blood sugar control in diabetes, in addition to diet and exercise ",
"PubChem CIDs": [
"168009818"
]
} |
|
CNCC1=CN(C(=C1)C1=CC=CC=C1F)S(=O)(=O)C1=CC=CN=C1 | [
"Mystery Molecule"
] | {
"Actives": "vonoprazan, amoxicillin, and clarithromycin",
"Approval Date": "5/3/2022",
"Brand Name": "Voquezna",
"Indication": "To treat Helicobacter pylori infection",
"PubChem CIDs": [
"45375887"
]
} |
|
CC(C)N1C(=O)C=C(NC1=O)NC(C)C2=CC=CC=C2 | [
"Mystery Molecule"
] | {
"Actives": "mavacamten",
"Approval Date": "4/28/2022",
"Brand Name": "Camzyos",
"Indication": "To treat certain classes of obstructive hypertrophic cardiomyopathy",
"PubChem CIDs": [
"117761397"
]
} |
|
C1=CC(=CC=C1C2=CN=C(C=C2)C(C(CN3C=NN=N3)(C4=C(C=C(C=C4)F)F)O)(F)F)OCC(F)(F)F | [
"Mystery Molecule"
] | {
"Actives": "oteseconazole",
"Approval Date": "4/26/2022",
"Brand Name": "Vivjoa",
"Indication": "To reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are not of reproductive potential",
"PubChem CIDs": [
"77050711"
]
} |
|
C1CC(CCC1CNC(=O)CN2CCN(CCN(CCN(CC2)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])C(=O)NC(CC3=CC4=CC=CC=C4C=C3)C(=O)NCCCCC(C(=O)O)NC(=O)NC(CCC(=O)O)C(=O)O.[Lu+3] | [
"Mystery Molecule"
] | {
"Actives": "lutetium (177Lu) vipivotide tetraxetan",
"Approval Date": "3/23/2022",
"Brand Name": "Pluvicto",
"Indication": "To treat prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer following other therapies",
"PubChem CIDs": [
"122706785"
]
} |
|
CC(=O)C1CCC2C1(CCC3C2CCC4C3(CCC(C4)(C)O)C)C | [
"Mystery Molecule"
] | {
"Actives": "ganaxolone",
"Approval Date": "3/18/2022",
"Brand Name": "Ztalmy",
"Indication": "To treat seizures in cyclin-dependent kinase-like 5 deficiency disorder",
"PubChem CIDs": [
"6918305"
]
} |
|
C1CCN(C1)CCOC2=C3COCC=CCOCC4=CC(=CC=C4)C5=NC(=NC=C5)NC(=C3)C=C2 | [
"Mystery Molecule"
] | {
"Actives": "pacritinib",
"Approval Date": "2/28/2022",
"Brand Name": "Vonjo",
"Indication": "To treat intermediate or high-risk primary or secondary myelofibrosis in adults with low platelets",
"PubChem CIDs": [
"46216796"
]
} |
|
C1CC1CN2CCN(CC2)C(=O)C3=CC=C(C=C3)NS(=O)(=O)C4=CC=CC5=C4N=CC=C5 | [
"Mystery Molecule"
] | {
"Actives": "mitapivat",
"Approval Date": "2/17/2022",
"Brand Name": "Pyrukynd",
"Indication": "To treat hemolytic anemia in pyruvate kinase deficiency",
"PubChem CIDs": [
"59634741"
]
} |
|
CCCS(=O)(=O)NC1CC(C1)N(C)C2=NC=NC3=C2C=CN3 | [
"Mystery Molecule"
] | {
"Actives": "abrocitinib",
"Approval Date": "1/14/2022",
"Brand Name": "Cibinqo",
"Indication": "To treat refractory, moderate-to-severe atopic dermatitis",
"PubChem CIDs": [
"78323835"
]
} |
|
CC1=C(C=CC2=C1N=C(N2)C3(CCCN3C(=O)C4=C(C=CC(=C4)OC)N5N=CC=N5)C)Cl | [
"Mystery Molecule"
] | {
"Actives": "daridorexant",
"Approval Date": "1/7/2022",
"Brand Name": "Quviviq",
"Indication": "To treat insomnia",
"PubChem CIDs": [
"91801202"
]
} |
|
CC(=O)NC1C(C(C(OC1OCCCCC(=O)NCCCNC(=O)CCOCC(COCCC(=O)NCCCNC(=O)CCCCOC2C(C(C(C(O2)CO)O)O)NC(=O)C)(COCCC(=O)NCCCNC(=O)CCCCOC3C(C(C(C(O3)CO)O)O)NC(=O)C)NC(=O)CCCCCCCCCCC(=O)N4CC(CC4COP(=O)(O)O)O)CO)O)O | [
"Mystery Molecule"
] | {
"Actives": "inclisiran",
"Approval Date": "12/22/2021",
"Brand Name": "Leqvio",
"Indication": "To treat heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease as an add-on therapy",
"PubChem CIDs": [
"126480325"
]
} |
|
CC1(C2=C(C=CC(=C2)S(=O)(=O)[O-])[N+](=C1C=CC3=C(C(=CC=C4C(C5=C(N4CCCCS(=O)(=O)O)C=CC(=C5)S(=O)(=O)O)(C)C)CCC3)OC6=CC=C(C=C6)CC(C(=O)O)NC(=O)C7=CC=C(C=C7)NCC8=CN=C9C(=N8)C(=O)NC(=N9)N)CCCCS(=O)(=O)O)C | [
"Mystery Molecule"
] | {
"Actives": "pafolacianine",
"Approval Date": "11/29/2021",
"Brand Name": "Cytalux ",
"Indication": "To help identify ovarian cancer lesions ",
"PubChem CIDs": [
"135565623"
]
} |
|
CC(C)NC1=NC2=CC(=C(C=C2N1C3C(C(C(O3)CO)O)O)Cl)Cl | [
"Mystery Molecule"
] | {
"Actives": "maribavir",
"Approval Date": "11/23/2021",
"Brand Name": "Livtencity",
"Indication": "To treat post-transplant cytomegalovirus (CMV) infection/disease that does not respond (with or without genetic mutations that cause resistance) to available antiviral treatment for CMV",
"PubChem CIDs": [
"471161"
]
} |
|
CCC(C)C1C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NCC(=O)NC(CSSCC(C(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCNC(=N)N)CC(=O)O)CC(C)C)CCCCN)CC(C)C)CC2=CC=CC=C2)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CCCCN)NC(=O)C(CC(=O)N)NC(=O)C(C)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CC3=CC=C(C=C3)O)NC(=O)C(CCCCN)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(CC(=O)N)NC(=O)C4CCCN4C(=O)C(CC5=CN=CN5)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C6CCCN6)C(=O)O)CC(C)C)CO)CCSC)CO | [
"Mystery Molecule"
] | {
"Actives": "vosoritide",
"Approval Date": "11/19/2021",
"Brand Name": "Voxzogo",
"Indication": "To improve growth in children five years of age and older with achondroplasia and open epiphyses",
"PubChem CIDs": [
"119058036"
]
} |
|
C1CN(CC1O)C2=C(C=C(C=N2)C(=O)NC3=CC=C(C=C3)OC(F)(F)Cl)C4=CC=NN4 | [
"Mystery Molecule"
] | {
"Actives": "asciminib",
"Approval Date": "10/29/2021",
"Brand Name": "Scemblix",
"Indication": "To treat Philadelphia chromosome-positive chronic myeloid leukemia with disease that meets certain criteria",
"PubChem CIDs": [
"72165228"
]
} |
|
CC1=C(C(=CC=C1)F)C(=O)N2CCCC(C2C3=CC=C(C=C3)NC4CCCC4)C(=O)NC5=CC(=C(C=C5)C)C(F)(F)F | [
"Mystery Molecule"
] | {
"Actives": "avacopan",
"Approval Date": "10/7/2021",
"Brand Name": "Tavneos",
"Indication": "To treat severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) in combination with standard therapy, including glucocorticoids",
"PubChem CIDs": [
"49841217"
]
} |
|
CCCCC1(CS(=O)(=O)C2=C(C=C(C=C2)N(C)C)C(C1O)C3=CC=C(C=C3)OCC4=CC=C(C=C4)C[N+]56CCN(CC5)CC6)CCCC | [
"Mystery Molecule"
] | {
"Actives": "maralixibat",
"Approval Date": "9/29/2021",
"Brand Name": "Livmarli",
"Indication": "To treat cholestatic pruritus associated with Alagille syndrome",
"PubChem CIDs": [
"9831643"
]
} |
|
CC1C(CC(C(=O)N1CC(F)(F)F)NC(=O)C2=CC3=C(CC4(C3)C5=C(NC4=O)N=CC=C5)N=C2)C6=C(C=CC(=C6F)F)F | [
"Mystery Molecule"
] | {
"Actives": "atogepant",
"Approval Date": "9/28/2021",
"Brand Name": "Qulipta",
"Indication": "To prevent episodic migraines",
"PubChem CIDs": [
"72163100"
]
} |
|
CC(C)OC(=O)C1=CN=C(N=C1C2=CN(C3=CC=CC=C32)C)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC | [
"Mystery Molecule"
] | {
"Actives": "mobocertinib",
"Approval Date": "9/15/2021",
"Brand Name": "Exkivity",
"Indication": "To treat locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations",
"PubChem CIDs": [
"118607832"
]
} |
|
CC(C)CC(C(=O)NC(CCCCN)C(=O)N1CCC(CC1)(C(=O)O)N)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC3=CC=CC=C3)N | [
"Mystery Molecule"
] | {
"Actives": "difelikefalin",
"Approval Date": "8/23/2021",
"Brand Name": "Korsuva",
"Indication": "To treat moderate-to-severe pruritus associated with chronic kidney disease in certain populations",
"PubChem CIDs": [
"24794466"
]
} |
|
CS(=O)(=O)C1=C2C(C(C(C2=C(C=C1)OC3=CC(=CC(=C3)C#N)F)F)F)O | [
"Mystery Molecule"
] | {
"Actives": "belzutifan",
"Approval Date": "8/13/2021",
"Brand Name": "Welireg",
"Indication": "To treat von Hippel-Lindau disease under certain conditions",
"PubChem CIDs": [
"117947097"
]
} |
|
CCCCC1(CN(C2=CC(=C(C=C2S(=O)(=O)N1)OCC(=O)NC(C3=CC=C(C=C3)O)C(=O)NC(CC)C(=O)O)SC)C4=CC=CC=C4)CCCC | [
"Mystery Molecule"
] | {
"Actives": "odevixibat",
"Approval Date": "7/20/2021",
"Brand Name": "Bylvay",
"Indication": "To treat pruritus",
"PubChem CIDs": [
"10153627"
]
} |
|
CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5 | [
"Mystery Molecule"
] | {
"Actives": "belumosudil",
"Approval Date": "7/16/2021",
"Brand Name": "Rezurock",
"Indication": "To treat chronic graft-versus-host disease after failure of at least two prior lines of systemic therapy",
"PubChem CIDs": [
"11950170"
]
} |
|
CN1C(=CN=C1COC2=CC=C(C=C2)SC)[N+](=O)[O-] | [
"Mystery Molecule"
] | {
"Actives": "fexinidazole",
"Approval Date": "7/16/2021",
"Brand Name": "Fexinidazole",
"Indication": "To treat human African trypanosomiasis caused by the parasite Trypanosoma brucei gambiense",
"PubChem CIDs": [
"68792"
]
} |
|
CCOC1=NC=C(C2=C1C(C(=C(N2)C)C(=O)N)C3=C(C=C(C=C3)C#N)OC)C | [
"Mystery Molecule"
] | {
"Actives": "finerenone",
"Approval Date": "7/9/2021",
"Brand Name": "Kerendia",
"Indication": "To reduce the risk of kidney and heart complications in chronic kidney disease associated with type 2 diabetes",
"PubChem CIDs": [
"60150535"
]
} |
|
CC(C)C(C)C1(CCC2(C3CCC4C5(COCC4(C3=CCC2(C1C(=O)O)C)CC(C5OCC(C)(C(C)(C)C)N)N6C(=NC=N6)C7=CC=NC=C7)C)C)C | [
"Mystery Molecule"
] | {
"Actives": "ibrexafungerp ",
"Approval Date": "6/1/2021",
"Brand Name": "Brexafemme",
"Indication": "To treat vulvovaginal candidiasis",
"PubChem CIDs": [
"46871657"
]
} |
|
CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C.C1CC1CN2CCC34CC(=O)CCC3(C2CC5=C4C(=C(C=C5)C(=O)N)O)O | [
"Mystery Molecule"
] | {
"Actives": "olanzapine and samidorphan",
"Approval Date": "5/28/2021",
"Brand Name": "Lybalvi",
"Indication": "To treat schizophrenia and certain aspects of bipolar I disorder",
"PubChem CIDs": [
"135398745",
"11667832"
]
} |
|
CCN1CCN(CC1)C2=CC=C(C=C2)NC3=CC(=NC=N3)N(C)C(=O)NC4=C(C(=CC(=C4Cl)OC)OC)Cl | [
"Mystery Molecule"
] | {
"Actives": "infigratinib",
"Approval Date": "5/28/2021",
"Brand Name": "Truseltiq",
"Indication": "To treat cholangiocarcinoma whose disease meets certain criteria",
"PubChem CIDs": [
"53235510"
]
} |
|
CC1CN(CCN1C2=NC(=O)N(C3=NC(=C(C=C32)F)C4=C(C=CC=C4F)O)C5=C(C=CN=C5C(C)C)C)C(=O)C=C | [
"Mystery Molecule"
] | {
"Actives": "sotorasib",
"Approval Date": "5/28/2021",
"Brand Name": "Lumakras",
"Indication": "To treat types of non-small cell lung cancer ",
"PubChem CIDs": [
"137278711"
]
} |
|
C1=CC(=NC=C1C(=O)NCCCCC(C(=O)O)NC(=O)NC(CCC(=O)O)C(=O)O)F | [
"Mystery Molecule"
] | {
"Actives": "piflufolastat F 18 ",
"Approval Date": "5/26/2021",
"Brand Name": "Pylarify",
"Indication": "To identify prostate-specific membrane antigen-positive lesions in prostate cancer",
"PubChem CIDs": [
"52950901"
]
} |
|
COC(=O)C(C1CCCCN1C(=O)OC[N+]2=CC=CC(=C2)C(=O)NC(CO)C(=O)[O-])C3=CC=CC=C3.COC(=O)C(C1CCCCN1)C2=CC=CC=C2 | [
"Mystery Molecule"
] | {
"Actives": "serdexmethylphenidate and dexmethylphenidate",
"Approval Date": "3/2/2021",
"Brand Name": "Azstarys",
"Indication": "To treat attention deficit hyperactivity disorder",
"PubChem CIDs": [
"134823895",
"154101"
]
} |
|
CCOC1=CC=CC=C1OCC2CNCCO2 | [
"Mystery Molecule"
] | {
"Actives": "viloxazine",
"Approval Date": "4/2/2021",
"Brand Name": "Qelbree",
"Indication": "To treat attention deficit hyperactivity disorder",
"PubChem CIDs": [
"5666"
]
} |
|
CC(C)CC(C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(CC1=CNC2=CC=CC=C21)NC(=O)C(CCCCN)NC(=O)C(C(C)C)NC(=O)C(CC3=CC=CC=C3)NC(=O)C(CCC(=O)O)NC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(C)(C)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC5=CC=C(C=C5)O)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC6=CC=CC=C6)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CO)NC(=O)C(CC7=CNC=N7)N | [
"Mystery Molecule"
] | {
"Actives": "dasiglucagon",
"Approval Date": "3/22/2021",
"Brand Name": "Zegalogue",
"Indication": "To treat severe hypoglycemia",
"PubChem CIDs": [
"126961379"
]
} |
|
CCCN=C1N(C(=O)C(=CC2=CC(=C(C=C2)OCC(CO)O)Cl)S1)C3=CC=CC=C3C | [
"Mystery Molecule"
] | {
"Actives": "ponesimod",
"Approval Date": "3/18/2021",
"Brand Name": "Ponvory",
"Indication": "To treat relapsing forms of multiple sclerosis",
"PubChem CIDs": [
"11363176"
]
} |
|
CC1=CC(=NO1)NC(=O)NC2=C(C=C(C=C2)OC3=C4C=C(C(=CC4=NC=C3)OC)OC)Cl | [
"Mystery Molecule"
] | {
"Actives": "tivozanib",
"Approval Date": "3/10/2021",
"Brand Name": "Fotivda",
"Indication": "To treat renal cell carcinoma",
"PubChem CIDs": [
"9911830"
]
} |
|
CCOC(=O)C(CC1=CC=C(C=C1)F)NC(=O)C(CC2=CC=C(C=C2)N(CCCl)CCCl)N | [
"Mystery Molecule"
] | {
"Actives": "melphalan flufenamide",
"Approval Date": "2/26/2021",
"Brand Name": "Pepaxto",
"Indication": "To treat relapsed or refractory multiple myeloma",
"PubChem CIDs": [
"9935639"
]
} |
|
C1C2C(C(C3C(O2)NC4=C(N3)C(=O)NC(=N4)N)(O)O)OP(=O)(O1)O | [
"Mystery Molecule"
] | {
"Actives": "fosdenopterin",
"Approval Date": "2/26/2021",
"Brand Name": "Nulibry",
"Indication": "To reduce the risk of mortality in molybdenum cofactor deficiency Type A",
"PubChem CIDs": [
"135463437"
]
} |
|
CN(C)P(=O)(N1CCN(CC1)C(=O)OCCOCCOCCO)OCC2CNCC(O2)N3C=CC(=NC3=O)N | [
"Mystery Molecule"
] | {
"Actives": "casimersen",
"Approval Date": "2/25/2021",
"Brand Name": "Amondys 45",
"Indication": "To treat Duchenne muscular dystrophy",
"PubChem CIDs": [
"131842141"
]
} |
|
CN1CCN(CC1)C1=CN=C(NC2=NC3=C(C=C4N3C3(CCCCC3)CNC4=O)C=N2)C=C1 | [
"Mystery Molecule"
] | {
"Actives": "trilacicilib",
"Approval Date": "2/12/2021",
"Brand Name": "Cosela",
"Indication": "To mitigate chemotherapy-induced myelosuppression in small cell lung cancer",
"PubChem CIDs": [
"124081865"
]
} |
|
CC(C)OC1=C(C=C(C=C1)C2=NN(C3=NC=NC(=C23)N)C(C)C4=C(C(=O)C5=C(O4)C=CC(=C5)F)C6=CC(=CC=C6)F)F | [
"Mystery Molecule"
] | {
"Actives": "umbralisib",
"Approval Date": "2/5/2021",
"Brand Name": "Ukoniq",
"Indication": "To treat marginal zone lymphoma and follicular lymphoma",
"PubChem CIDs": [
"72950888"
]
} |
|
CN1CCC(CC1)COC2=CN=C(N=C2)C3=CC=CC(=C3)CN4C(=O)C=CC(=N4)C5=CC=CC(=C5)C#N | [
"Mystery Molecule"
] | {
"Actives": "tepotinib",
"Approval Date": "2/3/2021",
"Brand Name": "Tepmetko",
"Indication": "To treat non-small cell lung cancer",
"PubChem CIDs": [
"25171648"
]
} |
|
CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)C(C(C)CC=CC=C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C | [
"Mystery Molecule"
] | {
"Actives": "voclosporin",
"Approval Date": "1/22/2021",
"Brand Name": "Lupkynis",
"Indication": "To treat lupus nephritis",
"PubChem CIDs": [
"6918486"
]
} |
|
CC1COC2N1C(=O)C3=C(C(=O)C(=CN3C2)C(=O)NCC4=C(C=C(C=C4)F)F)O.CC1=CC(=CC(=C1NC2=NC(=NC=C2)NC3=CC=C(C=C3)C#N)C)C=CC#N | [
"Mystery Molecule"
] | {
"Actives": "cabotegravir and rilpivirine (co-packaged)",
"Approval Date": "1/21/2021",
"Brand Name": "Cabenuva",
"Indication": "To treat HIV",
"PubChem CIDs": [
"54713659",
"6451164"
]
} |
|
COC(=O)NC1=C(N=C(N=C1N)C2=NN(C3=C2C=C(C=N3)F)CC4=CC=CC=C4F)N | [
"Mystery Molecule"
] | {
"Actives": "vericiguat",
"Approval Date": "1/19/2021",
"Brand Name": "Verquvo",
"Indication": "To mitigate the risk of cardiovascular death and hospitalization for chronic heart failure",
"PubChem CIDs": [
"54674461"
]
} |
|
C1CC(NC1CC2=CC=C(C=C2)NC(=O)C3CCC4=NC=CC(=O)N34)C(C5=CC=CC=C5)O | [
"Mystery Molecule"
] | {
"Actives": "vibegron",
"Approval Date": "12/23/2020",
"Brand Name": "Gemtesa",
"Indication": "To treat overactive bladder",
"PubChem CIDs": [
"44472635"
]
} |
|
CN(C)CC1=C(SC2=C1C(=O)N(C(=O)N2CC3=C(C=CC=C3F)F)C4=NN=C(C=C4)OC)C5=CC=C(C=C5)NC(=O)NOC | [
"Mystery Molecule"
] | {
"Actives": "relugolix",
"Approval Date": "12/18/2020",
"Brand Name": "Orgovyx",
"Indication": "To treat advanced prostate cancer",
"PubChem CIDs": [
"10348973"
]
} |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.